What is A-Alpha Bio?
A-Alpha Bio operates at the vanguard of the biotechnology sector, specializing in the identification and optimization of therapeutic proteins. By integrating high-throughput yeast display technology with sophisticated machine learning algorithms, the company provides a unique solution for mapping protein-protein interactions. This dual-pronged approach allows for the rapid screening of vast molecular libraries, significantly reducing the time and cost associated with traditional drug discovery. Based in Seattle, the company has cultivated a reputation for technical excellence, attracting a diverse syndicate of investors who recognize the transformative potential of their platform in the broader life sciences ecosystem.
How much funding has A-Alpha Bio raised?
A-Alpha Bio has raised a total of $68.3M across 3 funding rounds:
Angel/Seed
$2.8M
Series A
$51M
Other Financing Round
$14.5M
Angel/Seed (2019): $2.8M with participation from AME Cloud Ventures, Boom Capital, OS Fund, Washington Research Foundation, Madrona Venture Group, biotech angel investors, and Sahsen Ventures
Series A (2023): $51M led by Perceptive Advisors, Lux Capital, Perceptive Xontogeny Ventures, and Madrona Venture Group
Other Financing Round (2024): $14.5M supported by U.S. Department of Defense
Key Investors in A-Alpha Bio
Lux Capital
A New York-based venture capital firm that raises dedicated funds to invest in early-stage and growth-stage companies at the intersection of science and technology, backing founders in frontier areas such as AI, robotics, and biotechnology.
Perceptive Advisors
An investment firm managing significant assets, focused on funding innovative healthcare and life sciences technologies to drive medical breakthroughs.
OS Fund
A venture firm that invests in entrepreneurs commercializing breakthrough discoveries in fields including genomics, synthetic biology, and advanced materials.
What's next for A-Alpha Bio?
Looking ahead, the recent strategic investment is expected to catalyze the expansion of A-Alpha Bio's internal pipeline and enhance its collaborative research capabilities. As the company matures, the focus will likely shift toward scaling its computational infrastructure and deepening its partnerships with global pharmaceutical leaders. The infusion of capital provides the necessary runway to transition from a platform-centric model to a more integrated drug development enterprise, potentially unlocking new therapeutic modalities that were previously inaccessible. With a strong foundation of institutional support and a clear technological advantage, A-Alpha Bio is well-positioned to influence the future of precision medicine and synthetic biology.
See full A-Alpha Bio company page
